Lack of stability of topotecan in heart tissue homogenates: Is it an analytical dilemma or a real phenomenon?

Biomedical Chromatography

Volumn 23, Issue 4, 2009, Pages 447-449

  Srinivas, N R ^a  

^a ClinTec India International Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEART TISSUES; TISSUE HOMOGENATES; TOPOTECAN;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; TOPOTECAN;

DRUG ACCUMULATION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; HEART; HUMAN; LETTER; LUNG SMALL CELL CANCER; NONHUMAN; OVARY CANCER; QUANTITATIVE ANALYSIS; TISSUE HOMOGENATE;

EID: 65249088015     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1136     Document Type: Letter

References (30)

1. Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B and Stewart CF. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2003; 784: 225-232.
2. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A and Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemotherapy and Pharmacology 1996; 37: 195-202.
3. Baranda AB, Alonso RM, Jiménez RM and Weinmann W. Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples. Forensic Science International 2006; 156: 23-34.
4. Bardin S, Guo W, Johnson JL, Khan S, Ahmad A, Duggan JX, Ayoub J and Ahmad I. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues. Journal of Chromatography A 2005; 1073: 249-255.
5. Beijnen JH, Smith BR, Keijer WJ, van Gijn R, ten Bokkel Huinink WW, Vlasveld LT, Rodenhius S and Uderberg WJ. High performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. Journal of Pharmaceutical and Biomedical Analysis 1990; 8: 789-794.
6. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K and Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemotherapy Pharmacology 1998; 41: 464-468.
7. Chen J and Balthasar JP. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2005; 816: 183-192.
8. Chen J, Ping Q, Guo J, Liu M and Cai B. Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-nitrocamptothecin in rats. International Journal of Pharmaceutics 2007; 340: 29-33.
9. de Vries NA, Ouwehand M, Buckle T, Beijnen JH and van Tellingen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography 2007; 21: 1191-1200.
10. El-Gizawy SA and Hedaya MA. Comparative brain tissue distribution of camptothecin and topotecan in the rat. Cancer Chemotherapy and Pharmacology 1999; 43: 364-370.
11. Hsiang YH, Hertzberg R, Hecht S and Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. The Journal of Biological Chemistry 1985; 20: 14873-1878.
12. Legarza K and Yang LX. Novel camptothecin derivatives. In Vivo 2005; 19: 283-292.
13. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 1989; 58: 351-375.
14. Loos WJ, Stoter G, Verweij J and Schellens JH. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened (hydroxyl acid) in human plasma and urine. Journal of Chromatography B: Biomedical Applications 1996; 678: 309-315.
15. Loos WJ, de Bruijn P, Verweij J and Sparreboom A. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anticancer Drugs 2000; 11: 315-324
16. Pizzolato JF and Saltz LB. The camptothecins. Lancet 2003; 361: 2235-2242.
17. Rosing H, Doyle E, Davies BE and Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. Journal of Chromatography B: Biomedical Applications 1995; 668: 107-115.
18. Rosing H, van Zomeren DM, Doyle E, ten Bokkel Huinink WW, Schellens LH, Bult A and Beijnen JH. Quantitation of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. Journal of Chromatography B: Biomedical Science Applications 1999; 727: 191-203.
19. Ruan Q, Peterman S, Szewc MA, Ma L, Cui D, Humpreys GW and Zhu M. An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. Journal of Mass Spectrometry 2008; 43: 251-261.
20. Straathof CS, van den Bent MJ, Loos WJ, Vecht CJ and Schellens JH. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. Journal of Neurooncology 1999; 42: 117-122.
21. Sung C, Blaney SM, Cole DE, Balis FM and Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Research 1994; 54: 118-122.
22. ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudosn I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology 1997; 15: 2183-2193.
23. Tong X, Zhou J and Tan Y. Liquid chromatography/tandem triple-quadrupole mass spectrometry for determination of paclitaxel in rat tissues. Rapid Communications in Mass Spectrometry 2006; 20: 1905-1912.
24. Vali AM, Shafaghi B and Dadashzadeh S. Simple and sensitive high performance liquid, chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005; 818: 205-212.
25. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR and Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology 1999; 17: 68-667.
26. Wang JF, Yang Y, Sullivan MF, Min J, Cai J, Zeldin DC, Xiao YF and Morgan JP. Induction of cardiac cytochrome p450 in cocaine-treated mice. Experimental Biology Medicine (Maywood) 2002; 227: 182-188.
27. Wen B, Ma L, Nelson SD and Zhu M. High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Analytical Chemistry 2008; 80: 1788-1799.
28. Zhang H, Zhu M, Ray KL, Ma L and Zhang D. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Communications in Mass Spectrometry 2008; 22: 2082-2088.
29. Zhu M, Ma L, Zhang H and Humphreys GW. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high resolution mass spectrometry and mass defect filtering. Analytical Chemistry 2007; 79: 8333-8341.
30. Zunino F and Pratesi G. Camptothecins in clinical development. Expert Opinion in Investigational Drugs 2004; 13: 269-284.